CA Patent

CA2655780A1 — 3-aminoimidazo [1,2-a] pyridine derivatives as sglt inhibitors

Assigned to Merck Patent GmbH · Expires 2007-12-27 · 18y expired

What this patent protects

Disclosed are novel compounds of formula (I), wherein X, Y, R, R', R1, R1', R1", R2, R2', R2", R3, R3', R4, R4', and n have the meanings indicated in claim 1. Said novel compounds are suitable as antidiabetics.

USPTO Abstract

Disclosed are novel compounds of formula (I), wherein X, Y, R, R', R1, R1', R1", R2, R2', R2", R3, R3', R4, R4', and n have the meanings indicated in claim 1. Said novel compounds are suitable as antidiabetics.

Drugs covered by this patent

Patent Metadata

Patent number
CA2655780A1
Jurisdiction
CA
Classification
—
Expires
2007-12-27
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.